The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place.
Government is expanding prescription coverage for long-acting muscarinic antagonist (LAMAs) inhalers, used in the treatment of Chronic Obstructive Pulmonary Disease. The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place. This will ensure NLPDP beneficiaries have timely access to these inhalers for the treatment of their COPD.
UPDATED: Missing man located safe
RCMP are looking for information after a vehicle fire at a Stephenville dealership last night
RCMP looking for the public's help with a stolen ATV investigation in Barachois Brook
Man arrested after an assault in Corner Brook that left a female with injuries
Child and Youth Advocate releases report titled, "Off the Radar"
